RxDoctor Payments Data

Rebecca Waxman

Physician Assistant · Tonasket, WANPI 1285056606

Payments from drug & device makers

$2,613in general payments, 2019–2025

Across 56 payments — averaging $46.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$425
  • E.r. Squibb & Sons, L.L.C.$312
  • Pharmacyclics LLC, An Abbvie Company$285
  • Tempus AI, Inc$263
  • Beone Medicines USA, Inc.$223
  • AbbVie$208
  • plus $896 from 16 others

What the payments were for

  • Food & beverage$2,30388%
  • Education$31012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,613 in reported general payments places this provider in the 90th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$134,514
Medicare patients
136
Services billed
5,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib17$196,105
Enoxaparin Sodium12$7,590
Anastrozole74$1,692
Duloxetine Hcl13$1,075
Letrozole33$705
Oxycodone Hcl18$261
Gabapentin23$257
Omeprazole15$212
Prochlorperazine Maleate19$198
Ondansetron OdtOndansetron12$166
Dexamethasone12$137
Potassium Chloride12$131
Lorazepam18$54
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim13$15

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$32$196,10517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Tonasket

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →